osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'osimertinib', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
manuel d mine chrysalis-2 trial: amivantamab + lazertinib in nsclc egfr mutated after progression to osimertinib and platinum based ct. very proud to hav participated as principal inveatigator in this trial in ou institution #asco2022 #lcsm 
Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head of Thoracic Oncology & Clinical Trials. Professor of Oncology Universidad Autónoma Madrid Spain